IP Library Granted Patent US 10,975,361
Granted Patent B2
US 10,975,361 · App. 15/130,339 · Granted Apr 13, 2021

Modified DNA polymerases for improved amplification

Inventors: Wolfgang Schafer (Vredehoek, ZA); Paul McEwan (Diablo, CA); Eric Van Der Walt (Cape Town, ZA); John Foskett (Boulder, CO); William Bourn (Plumstead, ZA)
Assignee: Kapa Biosystems, Inc.
C12N9/1252C12P19/34C12Q1/686C12Y207/07007Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,975,361
App. No.
15/130,339
Granted
Apr 13, 2021
Kind
B2
Abstract

The present invention provides improved DNA polymerases that may be better suited for applications in recombinant DNA technologies, in particular technologies involving plant-derived samples. Among other things, the present invention provides modified DNA polymerases derived from directed evolution experiments designed to select mutations that confer advantageous phenotypes under conditions used in industrial or research applications.

Claims (3)

1. A method of amplifying nucleic acids in a biological sample, which method comprises a step of contacting the sample with a modified Taq polymerase the method comprising using a modified Taq polymerase having an amino acid sequence that is at least 95% identical to that of SEQ ID NO: 47 and includes an amino acid substitution relative to the Taq polymerase of SEQ ID NO: 38 at each of the following residues: A61, K346, S357, E507, 1707 and F749.

2. The method of claim 1 , wherein the modified Taq polymerase consists of the sequence of SEQ ID NO: 47.

3. In a method of amplifying nucleic acids in a biological sample, the improvement comprising contacting a sample with a modified Taq polymerase having an amino acid sequence that is at least 95% identical to that of SEQ ID NO: 47 and includes an amino acid substitution relative to the Taq polymerase of SEQ ID NO: 38, at each of the following residues: A61, K346, S357, E507, I707 and F749, and wherein the modified Taq polymerase has improved resistance to one or more inhibitors of nucleic acid amplification relative to the Taq polymerase having an amino acid sequence of SEQ ID NO: 38.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2019
From: KAPA BIOSYSTEMS
To: KAPA BIOSYSTEMS, INC.
Reel/Frame 050253/0072 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2016
From: SCHAFER, WOLFGANG; MCEWAN, PAUL; VAN DER WALT, ERIC; FOSKETT, JOHN; BOURN, WILLIAM
To: KAPA BIOSYSTEMS
Reel/Frame 038356/0090 →
Continuity (3)
Continuation 13979509
Provisional Application 61432936 · Jan 14, 2011
Related Publication 20170067037A1 · Mar 9, 2017